KYMR vs. NTRA: Kymera Therapeutics vs. Natera Stock Comparison
How do Kymera Therapeutics (KYMR) and Natera (NTRA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Kymera Therapeutics (KYMR) and Natera (NTRA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | KYMR | NTRA |
|---|---|---|
| Name | Kymera Therapeutics Inc. | Natera, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 11.25 billion USD | 45.05 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | August 21, 2020 | July 1, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| Total Return (1Y) | 131.52% | 61.03% |
| Total Return (3Y, Annualized) | 111.65% | 92.02% |
| Total Return (5Y, Annualized) | 15.68% | 23.20% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| Volatility (1Y, Annualized) | 62.83% | 52.30% |
| Beta (5Y) | 2.00 | 1.58 |
| Max Drawdown (5Y) | -83.27% | -75.72% |
| Avg. Volume (3M) | 833.05K | 1.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| Sharpe Ratio (1Y) | 2.03 | 1.09 |
| Sortino Ratio (1Y) | 4.16 | 1.63 |
Profitability
ROE (TTM)
Both Kymera Therapeutics (KYMR) at -27.29% and Natera (NTRA) at -10.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-27.29%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- KYMR
- -27.29%
- Q1
- -64.05%
- Min
- -167.77%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-10.55%
- Max
- 109.18%
- Q3
- 6.23%
- NTRA
- -10.55%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- KYMR
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.66%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- NTRA
- -5.66%
- Min
- -17.05%
Operating Margin (TTM)
Both Kymera Therapeutics (KYMR) at -396.04% and Natera (NTRA) at -7.64% report negative operating margin values, usually indicating operating losses over the period.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-396.04%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- KYMR
- -396.04%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-7.64%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- NTRA
- -7.64%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| ROE (TTM) | -27.29% | -10.55% |
| ROA (TTM) | -17.64% | -6.79% |
| Net Margin (TTM) | 0.00% | -5.66% |
| Operating Margin (TTM) | -396.04% | -7.64% |
| Gross Margin (TTM) | 0.00% | 65.14% |
Growth
Revenue Growth
Natera (NTRA) at 35.90% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Neither Kymera Therapeutics (KYMR) nor Natera (NTRA) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| Revenue Growth (YoY) | -16.70% | 35.90% |
| Revenue Growth (3Y CAGR) | -5.74% | 41.14% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Kymera Therapeutics (KYMR) at 11.13 and Natera (NTRA) at 2.81 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.13
- Max
- 25.13
- Q3
- 12.13
- KYMR
- 11.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.81
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- NTRA
- 2.81
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Kymera Therapeutics (KYMR) at 0.05 and Natera (NTRA) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.05
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- KYMR
- 0.05
- Q1
- 0.02
- Min
- 0.00
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NTRA
- 0.13
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| Current Ratio (MRQ) | 11.13 | 2.81 |
| Debt / Equity (MRQ) | 0.05 | 0.13 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Kymera Therapeutics (KYMR) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Kymera Therapeutics (KYMR) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NTRA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Kymera Therapeutics (KYMR) nor Natera (NTRA) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- KYMR
- --
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- NTRA
- --
P/S Ratio (TTM)
Natera (NTRA) at 15.49 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
110.00
- KYMR
- 110.00
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.49
- Max
- 58.18
- Q3
- 25.77
- NTRA
- 15.49
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Kymera Therapeutics (KYMR) at 6.96 sits in the upper P/B ratio quartile, and Natera (NTRA) at 23.99 prices even higher, above its industry range.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96
- Max
- 13.53
- KYMR
- 6.96
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
NTRA
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.99
- NTRA
- 23.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | KYMR | NTRA |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 110.00 | 15.49 |
| P/B Ratio (MRQ) | 6.96 | 23.99 |
| Free Cash Flow Yield (TTM) | -1.46% | 0.19% |